Dec 11 (Reuters) - Britain's AstraZeneca on Friday
said that it will begin work with Russia's Gamaleya Institute to
understand whether their two COVID-19 vaccine candidates can be
successfully combined.
The Gamaleya Institute is the developer of Russia's Sputnik
V vaccine.
(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick
Graham)